Findings have become possible through a new algorithm developed by researchers. He chose 27 molecules with the greatest therapeutic potential from a 1.56 million molecule database.
Up to now, the molecules that activate the proliferator-activated delta receptor protein (PPAR-delta) have been subjected to pharmaceutical assessments for the treatment of obesity and incurable fatty liver disease, which is the leading cause of liver cancer.
This protein makes muscle cells burn more fat and therefore have the potential to increase physical stamina and reduce the waist.
Treatment tests will then be performed to improve wound healing and to avoid kidney toxicity.
Researchers say that with such a large group of high-activity molecules, there is a great chance of finding treatment for a few common illnesses.
According to Integra Holdings, the Biotechnology Company of the Jewish University, 21 of the 27 molecules They have a successful pharmaceutical potential, especially as a possible cure for the fat.